Journal
CANCER CELL
Volume 27, Issue 1, Pages 138-148Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2014.11.001
Keywords
-
Categories
Funding
- Cancer Research UK
- EU
- BioInvent
- Roche
- Cancer Research UK [19502, 4293, 18518, 10834, 13074, 13211, 20537] Funding Source: researchfish
Ask authors/readers for more resources
Monoclonal antibody (mAb) drugs that stimulate antitumor immunity are transforming cancer treatment but require optimization for maximum clinical impact. Here, we show that, unlike other immunoglobulin isotypes, human IgG2 (h2) imparts Fc gamma R-independent agonistic activity to immune-stimulatory mAbs such as anti-CD40, -4-1BB, and -CD28. Activity is provided by a subfraction of h2, h2B, that is structurally constrained due its unique arrangement of hinge region disulfide bonds. Agonistic activity can be transferred from h2 to h1 by swapping their hinge and CH1 domains, and substitution of key hinge and CH1 cysteines generates homogenous h2 variants with distinct agonistic properties. This provides the exciting opportunity to engineer clinical reagents with defined therapeutic activity regardless of Fc gamma R expression levels in the local microenvironment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available